Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

钱？小工具？建立健康行为激励机制再度遭到质疑

Yael L. Maxwell

October 10, 2016

News Daily News

¿Dinero? ¿Dispositivos? Una Vez Más Vuelve a Cuestionarse Incentivar las Conductas Sanitarias

Yael L. Maxwell

October 10, 2016

News Daily News

Money? Gadgets? Incentivizing Healthy Behaviors Questioned Once Again

Yael L. Maxwell

October 10, 2016

News Daily News

A Step in the Wrong Direction: Weight-Loss Efforts Could Be Hampered by Addition of Wearable Device

Yael L. Maxwell

September 21, 2016

News Daily News

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Michael O'Riordan

August 12, 2016

News Daily News

Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook

L.A. McKeown

August 04, 2016

News Daily News

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

L.A. McKeown

July 28, 2016

News Daily News

Pokémon Go Forth: Cardiologists, AHA Support Use of Augmented Reality Games That Encourage Movement

Yael L. Maxwell

July 22, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

BMI Weighs Heavily on All-Cause Mortality Risk, According to a Global Meta-Analysis

Yael L. Maxwell

July 14, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

Anti-Inflammatory Drug Does Not Halt Plaque Progression in Overweight Patients With CAD

Todd Neale

May 27, 2016

Advertisement

钱？小工具？建立健康行为激励机制再度遭到质疑

¿Dinero? ¿Dispositivos? Una Vez Más Vuelve a Cuestionarse Incentivar las Conductas Sanitarias

Money? Gadgets? Incentivizing Healthy Behaviors Questioned Once Again

A Step in the Wrong Direction: Weight-Loss Efforts Could Be Hampered by Addition of Wearable Device

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

Pokémon Go Forth: Cardiologists, AHA Support Use of Augmented Reality Games That Encourage Movement

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

BMI Weighs Heavily on All-Cause Mortality Risk, According to a Global Meta-Analysis

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Anti-Inflammatory Drug Does Not Halt Plaque Progression in Overweight Patients With CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content